Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study ; volume:38 ; number:1 ; day:24 ; month:11 ; year:2023 ; pages:21-30 ; date:1.2024
Leukemia ; 38, Heft 1 (24.11.2023), 21-30, 1.2024
- Urheber
-
Zaliova, Marketa
Zuna, Jan
Winkowska, Lucie
Janotova, Iveta
Skorepova, Justina
Lukes, Julius
Meyer, Claus
Marschalek, Rolf
Novak, Zbynek
Domansky, Jiri
Stary, Jan
Sramkova, Lucie
Trka, Jan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41375-023-02083-9
- URN
-
urn:nbn:de:101:1-2024032122152007491565
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zaliova, Marketa
- Zuna, Jan
- Winkowska, Lucie
- Janotova, Iveta
- Skorepova, Justina
- Lukes, Julius
- Meyer, Claus
- Marschalek, Rolf
- Novak, Zbynek
- Domansky, Jiri
- Stary, Jan
- Sramkova, Lucie
- Trka, Jan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Measurable residual disease
Have we been qualifying measurable residual disease correctly?
Measurable residual disease in multiple myeloma: ready for clinical practice?
Measurable residual disease (MRD)-testing in haematological and solid cancers
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia
Response to comment on Have we been qualifying measurable residual disease correctly?
Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
"Measurable distance"
Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia
Measurable residual disease
Have we been qualifying measurable residual disease correctly?
Measurable residual disease in multiple myeloma: ready for clinical practice?
Measurable residual disease (MRD)-testing in haematological and solid cancers
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia
Response to comment on Have we been qualifying measurable residual disease correctly?
Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
"Measurable distance"
Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia
Measurable residual disease
Have we been qualifying measurable residual disease correctly?
Measurable residual disease in multiple myeloma: ready for clinical practice?
Measurable residual disease (MRD)-testing in haematological and solid cancers
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia
Response to comment on Have we been qualifying measurable residual disease correctly?
Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
"Measurable distance"
Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia